NuCana Reports Third Quarter 2026 Financial Results and Provides Business Update
Development Programme for NUC-7738 Advances with Three Presentations Planned at ESMO Immuno-Oncology & Advanced Therapies Congress in December 2026European Composition-of-Matter Patent Granted for NUC-7738NUC-3373 Development Pathway Established with Further Validation UnderwayCash Runway Expected…